Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort study

Fu Xiao Li, Jia Xin Cai, Ji Bin Li, Kong Jia Luo, Shi Yu Wang, Wei Hua Meng, Feng Sha, Zhi Rong Yang, Allan Hackshaw, Jin Ling Tang

Research output: Journal PublicationArticlepeer-review

Abstract

Objective: Evidence suggests immune checkpoint inhibitor (ICI) can increase the risk of myocarditis. We investigated it in a large national cohort in China. Methods: Patients with stage IIIB-IV non-small cell lung cancer (NSCLC) using data from China's National Anti-Tumor Drug Surveillance System between January 2013 and December 2021. Exposure density sampling was applied to control for immortal time bias. Multivariate Cox regression with time-dependent exposures was used to examine the association between ICI therapy and the incidence of myocarditis while controlling for confounders. Results: 55,219 patients were included. The median age was 61 years, and 62% were males. At one-year follow-up (median 335 days), there were 26 cases of myocarditis among ICI users and 28 cases among ICI non-users (a cumulative incidence of 4.8 and 0.6 per 1000 person-years respectively). The adjusted hazard ratio (HR) of myocarditis for ICI users was 7.41 (95% confidence interval [CI]: 3.29–16.67). For programmed cell death protein 1 inhibitor users the HR was 8.39 (95% CI: 3.56–19.77). No significant interactions were observed in subgroup analysis. The results remained unchanged in sensitivity analyses. Conclusions: This study showed that ICI therapy considerably increased the risk of myocarditis, supporting the need for closer monitoring of patients receiving ICI therapies.

Original languageEnglish
Article number33
Number of pages11
JournalCardio-Oncology
Volume11
Issue number1
DOIs
Publication statusPublished - 31 Mar 2025

Keywords

  • Cardiotoxicity
  • Cohort study
  • Immune checkpoint inhibitor
  • Myocarditis
  • Non-small cell lung cancer
  • Real-world evidence

ASJC Scopus subject areas

  • Oncology
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort study'. Together they form a unique fingerprint.

Cite this